DKK2 and colorectal carcinoma: Our previous experiments demonstrated that DKK2 blockade with the anti-DKK2 antibody 5F8 was effective in suppressing tumor progression by enhancing immune effector CD8 + T cell activation, in a syngeneic CRC model grafted with mouse colon cancer cell MC38 and a genetic benign CRC model using the ApcMin/+ mice [12].